Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 5 2000
Play
Audio Below:
I
think that breast cancer, as an intellectual challenge, is going
to be through in about a decade. That’s to say that, the combination
of the powerful data that we’ve gotten from the human genome,
the data from DNA chip arrays, the ability of combinatorialchemistry
techniques to match specific molecules to specific DNA structures
– all of these are going to revolutionize what we know about
breast cancer in the very near future, sometime probably within
the next decade. Working that out practically will keep oncologists
busy long after I retire. But, I suspect that as an intellectual
challenge, breast cancer is going to be through probably in a decade
or so. I think that’s something I wouldn’t have said five
years ago, but something that I feel very confident about going
forward. Again, the intellectual challenge is one thing, the practical
application is another, and the practical applications of this biologic
revolution are going to keep us all in business for a long time
to come.
Biological
rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody
therapy [Review]. Pegram, M. and Slamon, D Seminars in Oncology.
27(5 Suppl 9):13-19, 2000 Oct.
In
process Current and planned clinical trials with trastuzumab (Herceptin)
[Review]. Baselga, J. Seminars in Oncology. 27(5 Suppl 9):27-32, 2000
Oct. In process
Clinical
trials of single-agent trastuzumab (Herceptin) [Review]. Seminars in Oncology. 27(5 Suppl 9):20-26, 2000 Oct. In proces
